Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial

Published:2019-12-09 Issue:1 Volume:26 Page:64-72
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Yaish Hassan¹^ORCID,Matsushita Tadashi²,Belhani Meriem³,Jiménez‐Yuste Víctor⁴^ORCID,Kavakli Kaan⁵^ORCID,Korsholm Lars⁶,Matytsina Irina⁶,Philipp Claire⁷,Reichwald Kirsten⁸,Wu Runhui⁹

Affiliation:

1. University of Utah School of Medicine Salt Lake City UT USA

2. Nagoya University Hospital Nagoya Japan

3. Beni Messous University Hospital Algiers Algeria

4. La Paz University HospitalAutónoma University Madrid Spain

5. Ege University Hospital Izmir Turkey

6. Novo Nordisk A/S Søborg Denmark

7. Rutgers Robert Wood Johnson Medical School New Brunswick NJ USA

8. Novo Nordisk A/S Måløv Denmark

9. Beijing Children's Hospital Capital Medical University Beijing China

Funder

Novo Nordisk

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13883

Reference36 articles.

1. Purification and characterization of a new recombinant factor VIII (N8)

2. Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule

3. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

4. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

5. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial;Blood Advances;2024-03-15

2. Real-world long-term safety and effectiveness of turoctocog alfa in the treatment of haemophilia A in Japan: results from a multicentre, non-interventional, post-marketing study;Hematology;2024-02-20

3. Simoctocog alfa (Nuwiq^®) in children: early steps in life’s journey for people with severe hemophilia A;Therapeutic Advances in Hematology;2024-01

4. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study;Expert Review of Hematology;2023-09-07

5. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3